松弛素治疗心力衰竭的研究进展
《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]
- 期数:
- 2018年第3期
- 页码:
- 368-371
- 栏目:
- 综述
- 出版日期:
- 2018-03-25
文章信息/Info
- Title:
- Research progress of relaxin in treatment of heart failure
- Author(s):
- RONG Cheng-zhen; LU Jia-zhong
- (Department of Cardiology, Fuyang Second People’s Hospital, Fuyang 236000, Anhui, China)
- Keywords:
- relaxin; heart failure
- 分类号:
- R541.6
- DOI:
- -
- 文献标识码:
- A
- 摘要:
- 心力衰竭是一种复杂的临床综合征,血管功能紊乱是导致心力衰竭(HF)的原因之一，松弛素（serelaxin，relaxin-2）是一种重组血管活性肽，导致全身和肾血管舒张，是治疗急性HF的一种药物。松弛素治疗HF的临床效益可归因于改善循环系统，心脏和肾脏血流动力学、保护细胞和器官免受损害，具有抗炎，抗重构、抗纤维化、抗心肌缺血和促血管生成的影响，可减少心脏和肾缺血缺氧状态,降低HF死亡率。本文重点介绍松弛素的作用机制以及在HF治疗中的临床试验。
- Abstract:
- Heart failure is a complex clinical syndrome and vascular dysfunction is one of the leading causes of heart failure. Relaxin is a human relaxin (serelaxin, relaxin-2) recombinant vasoactive peptide for systemic and renal vasodilation, and is one of the pharmacological treatments of acute heart failure. The clinical benefits of relaxin in the treatment of congestive heart failure can be attributed to improvement in the circulatory system, the heart, renal hemodynamics, protection of cells and organs from damage, effects of anti-inflammation, anti-impact, anti-fibrotic remodeling and anti-myocardial ischemia, promotion of angiogenesis, reduction of heart and kidney ischemia and hypoxia, and decrease of heart failure mortality. In this review, we focus on the role of relaxin and its mechanism and review clinical trials of relaxin in treatment of heart failure.
参考文献/References
[1]Teerlink JR,Cotter G,Davison BA,et al.RELAXin in Acute Heart Failure(RELAX-AHF)Investigators.Serelaxin,recombinant human relaxin-2,for treatment of acute heart failure(RELAX-AHF):a randomised, placebo-con-trolled trial[J].Lancet,2013,381(9860):29-39.
[2]Díez J.Serelaxin:a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions[J].Am J Cardiovasc Drugs,2014,14(4):275-285.
[3]Hisaw FL.Experimental relaxation of the pubic ligament of the guinea pig[J].Proc Soc Exp Biol Med,1926,23:661-663.
[4]Zhang J,Qi YF,Geng B,et al.Effect of relaxin on myocardial ischemia injury induced by isoproterenol[J].Peptides,2005,26(9):1632-1639.
[5]Fisher C,MacLean M,Morecroft I,et al.Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart?[J].Circulation,2002,106(3):292-295.
[6]Debrah DO,Conrad KP,Jeyabalan A,et al.Relaxin increases cardiac out-put and reduces systemic arterial load in hypertensive rats[J].Hypertension,2005,46:745-750.
[7]严 雯,冯 敏,廖完敏,等.松弛素对老年大鼠心血管保护作用的研究[J].内科急危重症杂志,2013,19(1):42-43.
[8]Chow BS,Chew EG,Zhao C,et al.Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloprotein-ases:the additional involvement of iNOS[J].PLoS One,2012,7(8):e42714.
[9]Samuel CS,Bodaragama H,Chew JY.Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease[J].Hypertension,2014,64(2):315-322.
[10]Ng HH,Leo CH,Parry LJ.Serelaxin(recombinant human relaxin-2)prevents high glucose-induced endothelial dysfunction by ameliorating prostacyclin production in the mouse aorta[J].Pharmacol Res,2016,107:220-228.
[11]Haase N,Rugor J,Przybyl L,et al.Relaxin does not improve Angiotensin II-induced target-organ damage[J].PLoS One,2014,9(4):e93743.
[12]Quattrone S,Chiappini L,Scapagnini G,et al.Relaxin potentiates the expression of inducible nitric oxide synthase by endothelial cells from human umbilical vein in in vitro culture[J].Molecular Human Reproduction,2004,10(5):325-330.
[13]Baccari MC,Bani D.Relaxin and nitric oxide signalling[J].Current Protein Peptide Science,2008,9(9):638-645.
[14]Bani-Sacchi T,Bigazzi M,Bani D,et al.Relaxin-induced increased coro-nary flow through stimulation of nitric oxide production[J].Br J Pharmacol,1995,116(1):1589-1594.
[15]Bani D,Masini E,Bello MG,et al.Relaxin protects against myocar-dial injury caused by ischemia and reperfusion in rat heart[J].Am J Pathol,1998,152(5):1367-1376.
[16]Nistri S,Pini A,Sassoli C,et al.Relaxin promotes growth and maturation of mouse neonatal cardiomyocytes in vitro:clues for cardiac regeneration[J].Cell Mol Med,2012,16(3):507-519.
[17]Wang D,Zhu H,Yang Q,et al.Effects of relaxin on cardiac fibrosis, apoptosis, and tachyarrhythmia in rats with myocardial infarction[J].Biomed Pharmacother,2016,84:348-355.
[18]Masini E,Nistri S,Vannacci A,et al.Relaxin inhibits the activation of human neutrophils:involvement of the nitric oxide pathway[J].Endocrinology,2004,145(3):1106-1112.
[19]张 妍,董文艳,王志萍.松弛素对大鼠肺缺血-再灌注损伤的作用[J].临床麻醉学杂志,2016,32(1):69-72.
[20]Dschietzig T,Teichman S,Unemori E,et al.Intravenous recombinant human relaxin in compensated heart failure:a safety,tolerability,and pharmacody-namic trial[J].Card Fail,2009,15(3):182-190.
[21]Ponikowski P,Mitrovic V,Ruda M,et al.A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure[J].Eur Heart J,2014,35(7):431-441.
[22]Filippatos G,Teerlink JR,Farmakis D,et al.Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction:results from the RELAX-AHF trial[J].Eur Heart J,2014,35(16):1041-1050.
[23]朱艳艳，潘嘉林，陈灵芝,等.慢性心力衰竭患者血浆H2松弛素的表达[J].温州医科大学学报,2015,45(2):22-25.
[24]陈 善,杨高瑾,周晓秋.血浆松弛素水平在心力衰竭患者早期诊断中的作用研究[J].中国医师杂志,2015,17(6):909-910.
[25]Pintalhao M,Castro-Chaves P,Vasques-Novoa F,et al.Relaxin serum levels in acute heart failure are associated with pulmonary hypertension and right heart overload[J].Eur J Heart Fail,2017,19(2):218-225.
[26]Xie J,Chen Y,Li L,et al.H2 relaxin expression and its effect on clinical outcomes in patients with chronic heart failure[J].Int J Clin Exp Med,2015,8(3):4420-4424.
[27]Metra M,Ponikowski P,Cotter G,et al.Effects of serelaxin in subgroups of patients with acute heart failure:results from RELAX-AHF[J].Eur Heart J,2013,34(40):3128-3136.
备注/Memo
- 备注/Memo:
- 收稿日期：2017-01-18.通讯作者：卢家忠，主任医师，主要从事心血管介入研究 Email：tlclhy@163.com 作者简介：戎成振，主治医师，硕士 Email：736289691@qq.com
常用功能
统计/Statistics
- 摘要浏览/Viewed670
- 评论/Comments
